BIOTECHNOLOGY AND LIFE SCIENCES -...

BIOTECHNOLOGY AND LIFE SCIENCES


Company overview AB BIOTICS is a spin-off company of UAB founded in 2004. Is dedicated to the internal development of functional food ingredients. and also provides outsourcing R&D services to companies. The company received fi nancing under the Capital Concepte scheme of CIDEM, as well as a NEOTEC loan.The objectives are to carry out in vitro documentation of the probiotic microorganisms it has developed until now, and to initiate screening for obtaining natural active ingredients for the prevention or treatment of physiological disorders in the healthcare industry.

Product or serviceAB-Fortis: to obtain iron-containing microcapsules designed to fortify iron-containing foods. AB-Pyloriosis: to develop a probiotic capable of reducing the growth of Helicobacter pylori in the stomach. AB-Life: a probiotic formula to improve cardiovascular health. AB-Enhancer: to obtain a probiotic designed to promote animal growth. AB-Dentis: a probiotic formula designed to remove the streptococcus mutans found in the human oral cavity. AB-Probiosis: compounds designed to delay the absorption of sugar in the intestine.

MarketThe value added provided by the company lies in its technical know-how and outstanding scientifi c team, as well as in the market study of functional products in the food and pharmaceutical industries. The company a signifi cant portfolio of clients. These include SMEs and a number of large companies from the food and pharmaceutical industries.

Team and shareholdersCapital participation: Buenaventura Guamis, Miquel A. Bonachera, Sergi Audivert, and Futur Firms SL. Human capital: entrepreneurs, Miquel A. Bonachera and Sergi Audivert. CRO (doctors): Jordo Espadaler, Jordi Cuñé, Galí Drudis and Ariana Salavert. Laborator technical personnel: María Rodriguez and Sandra Antona. Anna Arnau, CAO and Joan Figueres and Roger Torrent, Financial management of projects.

Financing proposalOur growth plan includes a contribution of �900,000 in the form of an equity loan, ENISA (�500,000), and a capital increase of �400,000 from various business angels.

Proposal summaryRound: No / New round: Yes / Type of investors: national

AB BIOTICS Tax code (CIF): B-63497473Masia Can Fatjó del Molí, s/n

08290 Cerdanyola del Vallès, [email protected]

www.ab-biotics.comTel. 607 262 119

CONTACT PERSON: MIQUEL ÀNGEL BONACHERA

#10Research and development of active principles to obtain functional ingredients with a specifi c effect aimed at the prevention of disease.

What has been your biggest business mistake and what did you learn from the experience?We don’t attach too much importance to errors. New opportunities emerge from errors, no matter how big or small they are.Miquel Àngel Bonachera and Sergi Audivert Brugué

040

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

EG

row

th /

R&

D

1

2

CORPORATE INFORMATION

� 2006 2007 2008 2009 2010

TURNOVER 722.678 881.482 1.501.000 1.954.360 2.388.941

EBITDA 16.786 112.377 123.290 144.291 214.839

RESOURCES 241.597 318.231 783.932 855.811 964.690

NEEDS 415.051 551.816 1.306.585 1.231.090 1.605.674

SWOT SELF-EVALUATION

TEAM: EXTERNAL BACKUP: BUSINESS MODEL: PRODUCT / INNOVATION: MARKET AND BUSINESS STRATEGY:

3


Company overviewThe company, founded in February 2005, has obtained subsidies from the Generalitat and the Ministry of Education and Science, a NEOTEC loan from the CDTI (�400,000) and has applied for funding (�100,000) from CIDEM’s Capital Concept. It is in the fi rst negotiation round with the CSIC and private investors to obtain funding for its activities. It is working with 4 European companies, has secured a number of customers and has forecast that by the end of 2008 it will have 6 members of full time staff in addition to its part time staff at the CSIC and the University of Barcelona.

Product or serviceAGRASYS basically operates in the agri-food sector using a business model that is based on the development of new plant varieties that make it possible to create new added value food products. The fi rst product that it launched onto the market was a cereal that showed promise in terms of nutrition and health. Furthermore, AGRASYS’ genetic improvement technology, may be applied to other agro-industrial sectors such as the biofuel sector. AGRASYS has a competitive edge over other companies in its development of advanced genetic improvement technologies. In the future, the company plans to use genetic engineering to create new plant varieties.

MarketAGRASYS has designed its fi rst product for the functional food sector and intends to serve the cereal-based food market. The biofuel market is clearly also subject to exponential growth that is favoured by EU directives and the Spanish Plan for Renewable Energy. There is a need on this market for R&D to increase the effi ciency of existing crops and to create and develop a new generation of bio-energy crops.

Team and shareholdersThe team is made up of 2 researchers who gained their experience in the academic community and multinational and start-up companies. They decided to form part of the management and development team. Researchers from the CSIC and the IFAPA also belong to the development team.

Financing proposalWe are seeking investors who are able to make a contribution of approximately �300,000 to our project to supplement the �500,000 NEOTEC loan and the Capital Concepte.

Proposal summary Round: no / New round: no / Type of investors: national and international

AGRASYS Tax code (CIF): B63765754Parc Científi c Barcelona, Baldiri i Reixac, 10-12

08028 [email protected]

www.agrasys.es (under construction)Tel. 934 177 037

CONTACT PERSON: PILAR BARCELÓ ENSESA

#11AGRASYS is a technology-based company that uses advanced techniques in genetic improvement and biotechnology to develop new added value varieties of plants.



If an overnight miracle took place and you woke up to the company of your dreams, what would be the fi rst change that you would notice on arriving at the offi ce in the morning?We would have become an international point of reference in our fi eld. We would have an all-embracing, multidisciplinary team that would be able to reap the full benefi ts of our research by creating successful products for the market. Our turnover would be such that we would be able to make big investments in other projects.Pilar Barceló Ensesa, Managing Director

042

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

E


� 2006 2007 2008 2009 2010

TURNOVER - 123.991 256.686 427.811 349.418

EBITDA - 89.108 -90.786 -51.215 -115.891

RESOURCES 3.300 60.640 227.093 149.349 997

NEEDS - - 550.000 250.000 -

R&D

3

1

2


Tax code (CIF): B64630569C/ Balmes, 86, 3r 1a08008 [email protected]. 932 158 008

CONTACT PERSON: JOSÉ MANUEL MAS BENAVENTE

As a businessman, with which of the following qualities do you most identify, and why? The ability to take on risks, the ability to innovate, the ability to motivate

or the ability to organise.Without a doubt, every business should have

a good dose of each of these qualities. I would like to think that my ability to motivate the people around

me is able to make up for the other qualities, which I may lack from time to time.

José Manuel Mas Benavente, Project Manager



#12ANAXOMICS BIOTECH, SL

A service devoted to the discovery of new therapeutic targets and drugs using

advanced techniques in systems biology.

Company overviewANAXOMICS BIOTECH SL is a relatively new company that was set up in 2007 as a spin-off of INFOCIENCIA SL, which specialises in biotechnology services.

Product or serviceANAXOMICS BIOTECH is developing the most advanced technology in the world in the fi eld known as human interactomics, which involves mapping the vast network of interactions between human proteins. The resulting “maps” serve as the basis for describing hitherto unknown therapeutic targets, which lead to the development of new drugs to combat them. ANAXOMICS BIOTECH has a business structure and the know-how that make it the ideal candidate to become a leading company in the discovery of new drugs by 2010.

MarketANAXOMICS’ products and services are mainly designed for the pharmaceutical industry.

Team and shareholdersANAXOMICS BIOTECH’s shareholders and its senior posts are held by experts with prestigious reputations in various fi elds: Mr Jordi Naval, current chairman of Infociencia, SL and of ANAXOMICS BIOTECH. Mr Ramón Banet, Finance Director at ANAXOMICS BIOTECH. Dr José Manuel Mas, who is currently Project Manager and Head of R&D at INFOCIENCIA, acts as Project Manager for ANAXOMICS BIOTECH. Dr Patrick Aloy, ICREA Research Professor, who is currently the senior researcher of the Structural Bioinformatics Group at the Barcelona Institute for Research in Biomedicine, is to be appointed Science Director at ANAXOMICS BIOTECH. Dr Joan Bigorra, is currently the Director of the Clínic Foundation for Biomedical Research.

Financing ProposalThe research services that ANAXOMICS offers are able to cater for part of the pharmaceutical market’s current needs. As the company has only recently been set up, it requires fi nancing so that it has enough capital to perfect its techniques and begin to market its products.

Proposal summary Round: no / New round: yes / Type of investors: national and international

043

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

EG

row

th /

fi xe

d a

sset

s /

R&D


� 2006 2007 2008 2009 2010

TURNOVER - 127.000 650.000 1.400.000 2.200.000

EBITDA - 126.447 643.917 1.394.004 1.125.000

RESOURCES - 129.477 142.424 200.000 241.267

NEEDS - - 500.000 600.000 720.000

1

3

2


Company overviewFounded by researchers from UB, UAB and Ud, monoclonal antibody research and production experts, and people from the world of business management.Thanks to a Torres Quevedo programme promoted by the Spanish Government, in 2005 it began its monoclonal and polyclonal antibody production and commercial activities. In 2007 it was awarded two Petri projects which enabled it to start two research projects which will allow it to begin construction on its own therapeutic and diagnostic product.

Product or serviceWe establish collaborations with public centres and university research groups for the production of monoclonal antibodies. These collaborations will enable us to have our own development pipeline and a portfolio of therapeutic products and diagnostic kits of our own. We also want to become the commercial company of reference for the production of antibodies to order and for catalogue antibody purchases.

MarketOn the one hand, we direct our current commercial activities to biomedical research groups in public centres by distributing and producing antibodies. These activities will continue to grow in coming years. On the other hand, the collaborative research projects we are starting will enable us to enter the clinical diagnostics market, the food and agriculture market through the development of biosensors, and the pharmaceutical market through the development of human and humanised monoclonal antibodies with therapeutic applications.

Team and shareholdersThe management team is comprised of a managing director, a technical director, and a marketing and sales manager. The shareholders are university scientists, technology transfer experts and people from the world of business management and administration.

Financing proposalThe company’s immediate fi nancial needs will be covered by the NEOTEC loan granted to it, the CIDEM “Capital Concepte” aid it has applied for, and the capital increase associated with these aids, in which the current shareholders and other scientists taking part in the company’s research projects will participate. The entry of private investors or venture capital is envisaged in one to two years’ time.

Proposal summaryRound: no / New round: yes / Type of investors: national and international

ANTIBODYBCN (ABBCN, SL) CIF: B-63575740Diagonal, 392 3r 1a


Tel. 902 220 246

CONTACT PERSON: ANTONIO LÓPEZ

#13Biotech company which commercialises, produces and develops antibodies belonging to it for therapeutic and diagnostic uses and to apply in scientifi c research in the fi elds of biomedicine, biotechnology and the food and agriculture industry.



What has been your biggest business mistake and what did you learn from the experience?Not carrying out an accurate market study, which should have been conducted independently and objectively, before creating the company or in its early days, by outside people. Maybe also trying to work on too many fronts opened up too early, instead of focusing on small initial milestones to open up new opportunities only after acquiring the most suitable experience.Joaquín López Soriano. Technical Director

044

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

EG

row

th


� 2006 2007 2008 2009 2010

TURNOVER 113.066 177.000 354.000 634.750 1.024.867

EBITDA -94.443 -90.140 -88.068 3.267 225.910

RESOURCES 49.130 130.371 397.888 188.503 387.718

NEEDS - - - 400.000 300.000

3

1

2


Tax code (CIF): B-64359466Parc Científi c de BarcelonaBaldiri Reixac, 15-2108028 [email protected]. 650 547 255 / 934 020 240

CONTACT PERSON: RAMON RAMON REAL

If an overnight miracle took place and you woke up to the company of your dreams, what would be the fi rst change that you would notice on arriving at the offi ce in the morning?

Right now the youth and size of the company mean we have a team of highly motivated people

who are all actively involved with the Bioingenium project. The company benefi ts from an excellent

operational environment and shows a strong capacity to grow and collaborate with other companies

in biotechnology related areas.The only thing that could improve the Bioingenium business project would be to have the funds necessary

to carry out the projects we have undertaken more rapidly, converting the company into a leader

within the global industrial community. Ramon Ramon Real



#14BIOINGENIUM, SL

Bioingenium aims to develop and apply production technology to recombinant proteins as a means of obtaining products of great industrial

and scientifi c value, which meet the quality and innovation standards required both by the market and the industry.

Company overview Bioingenium is a spin-off company specialising in the biotechnology industry.Bioingenium is currently being launched in the bio-incubator of Barcelona Scientifi c Park, where it is conducting its business project. It has recruited a team of three people to carry out the business project.To achieve this, it has secured government grants from the Gènesi programme, a PROFIT grant from ICN, an R&D grant from CIDEM for its ongoing business project, a participation loan from CIDEM Capital Concepte, an ICREA grant for one of its researchers, and has also applied for a NEOTEC loan.

Product or serviceProducts currently being developed by Bioingenium include:1. Glycoproteins produced recombinantly for animal health applications.2. An enzyme produced recombinantly that can be used in the synthesis and purifi cation

of various molecules of interest for pharmaceutical and fi ne chemicals processes.In addition, it offers a variety of services geared towards meeting the biotechnological needs of companies in the industry and other related companies.

MarketThe products and services offered are aimed at the biotechnology industry and sectors related to animal health and chemical/pharmaceutical products. These are extremely broad markets with a huge potential for growth, capable of offering technologically advanced solutions characterised by a trend towards the use of biotechnology products.

Team and shareholdersThe founders are Dr Francisco Valero, Dr Pau Ferrer and Dr Ramon Ramon. They worked together in the Chemical Engineering Department of the Universitat Autònoma of Barcelona on the development of activities similar to those being developed within the company.

Financing proposalThe proposal involves opening the company’s share capital to individuals and/or companies who can provide the founds to meet the requirements associated with the search for public fi nance. Also, it would be interesting if these individuals and/or companies could provide expertise or contacts to help us broaden the company’s horizon.

Proposal summaryRound: No / New round: Yes / Type of investors: national and international

045

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

EFi

xed

ass

ets

/ R&

D


� 2006 2007 2008 2009 2010

TURNOVER - 5.600 46.500 95.000 560.000

EBITDA - - - - 49.000

RESOURCES - 13.100 109.700 136.900 27.500

NEEDS - - - 150.000 300.000

1

3

2


Company overviewDDG was founded in 2001 and is based in Barcelona, Spain. It carries out research activities in laboratories in France (Catalyse) and Spain (Centre Tecnològic LEITAT, UB, Hospital Clínic de Barcelona). It has research partnerships with Grace, Ciba, Spontex and L’Oreal, among others. In 2007, Lonza signed a patent licensing agreement for the worldwide use of one of DDG’s technologies. DDG has a portfolio of research activities that have given positive results and attracted many collaborators. The company aims to attract investors by offering shares in the company, to research into new commercial applications.

Product or serviceDDG has developed and patented a technology for applying a permanent treatment with antimicrobial properties on a vast number of surfaces (increased durability, no dissemination, and protection of the environment).The bactericide properties of permanently treated surfaces eliminate the bacteria and fungi that come into contact with the surface. DDG’s treated products exhibit a better performance than those of competitors, as they are fi xed permanently to the surface.

MarketSurfaces of materials treated successfully include: epoxy, melamine, lacquers, PE/PP, textile, non-woven fabrics, PVC and ceramics. Many more materials are expected to be suitable for the process. The strategy focuses on manufacturing and selling germicidal compounds to third parties so that they can be incorporated into their products.

Team and shareholdersMajor shareholders: Grupo J.L. Noguer and M.A. Ramírez (51%), Grup Melul (30%) and Grup Poniente (12%). The team is comprised of : José Luis Noguer (General Manager), Miguel Ángel Ramírez (Director), Ana Mª Lozano (Technical Offi cer), Alain Perichaud (Scientifi c Technical Offi cer) and Mònica Arnautu (R&D Offi cer).

Financing proposalAn additional investment of �400,000 – �600,000 is required to fi nance the commercial R&D programme for 2008 and 2009. The company plans to generate profi ts by the end of 2008, reaching an estimated �2.5 MM by 2010.

Proposal summaryRound: no / New round: no / Type of investors: national and international

DESARROLLO DEL GRAFTING, SL (DDG)

Tax code (CIF): B-62649405 Avenir, 22, baixos, 08021 Barcelona

[email protected] [email protected]

Te. 934 095 301

CONTACT PERSON: ANA MA LOZANO AND JOSÉ LUIS NOGUER

#15DDG offers global and innovative antimicrobial solutions using specifi c surface treatments.



As an entrepreneur, with which of the following qualities do you most identify, and why? The ability to take risks, the ability to innovate, the ability to motivate or the ability to organise.The ability to innovate, as in the ability to identify business opportunities and create new products and companies, to meet people’s needs in today’s fast-changing environment.Changing with the market and staying ahead of competitors.José Luis Noguer, Manager04

6IN

VE

ST

ME

NT

PU

RP

OS

E >

< S

TAG

ER&

D


� 2006 2007 2008 2009 2010

TURNOVER - - - 1.500.000 3.500.000

EBITDA - - - - -

RESOURCES 130.000 145.000 350.000 250.000 -

NEEDS - - 350.000 250.000 -

3

1

2


CIF: B-64622525Llacuna, 162, box 21408018 [email protected]. 934 851 516

CONTACT PERSON: JAUME MIR

What has been your biggest business mistake and what did you learn from the experience?

My main business mistake was thinking that simply with a good results account with profi t a businessman

could be fully satisfi ed. I learnt that I wanted to do something that made me feel I was making a

contibution to Catalonia and that I was doing my bit towards preserving the planet.

Àngel Lázaro, General Manager



3

#16GLOBAL BIONANOMICS SL

Our wish is to contribute to achieving a more sustainable world through the development of new technology for the administering

of medicines for genetic therapy and pharmacotherapy.

Company overview In the area of genetic therapy and pharmacotherapy we are developing new technology for the administering of drugs (N4B) based on recombining proteins very similar to virions¹ (artifi cial virus). We are also developing technology for the administering of enzymes through plasmids (C2B) in the fi eld of new bioprocesses undertaken to replace current processes for manufacturing chemical products.. From the government of Catalonia we have received fi nancial research assistance and a loan from a private bank to cover the transactions.

Product or service In the case of C2B, the objective is to obtain three new enzymes or a plasmid recombinant bacteria in place by 2008. In the case of N4B, the purpose is to manage to develop two systems for administering Artifi cial Viruses per year, from 2011, with the collaboration of pharmaceutical companies which will provide us with the active substance. It is envisaged that in 2016 our fi rst product will be on the market.

MarketIn 2004 the market (for C2B) grew to 578 billion euros (FEIQUE)2, and it is forecast that in 2015 up to 30% of said amount will be related to synthesis processes in progress which will become bioprocesses. In 2005, the molecular market focusing on administration (for N4B) (for N4B) was valued at 7.5 billion dollars in the seven largest pharmaceutical markets.

Team and shareholdersThe company was incorporated by a group of fi ve members. We are supported by 15 years of experience and possess the aptitudes necessary for a successful business. All members forming the team come from the world of chemical and pharmaceutical industry. Moreover, within the company we have an external scientifi c consultant.

Financing proposal In order to be able to carry out the research and bear the cost of client operations, we need to make an investment of 1 million euros in 2008. As regards 2009, we will need to make another of 7 million euros in order to be able to construct the research centre and pilot plant and it is envisaged that in 2012 an additional 5 million euros will be necessary for our equipment.

Proposal summaryRound: Yes / New round: Yes / Type of investors: national and international

047

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

EG

row

th /

Fix

ed a

sset

s /

R&D

2

1


� 2006 2007 2008 2009 2010

TURNOVER 0 17.000 255.000 585.000 1.867.000

EBITDA 0 4.000 100.646 -124.585 336.078

RESOURCES 0 3.600 10.000 30.000 60.000

NEEDS 0 72.000 1.000.000 7.000.000 -


Company overviewUp to the present the company has been developing the basic technology for designing an initial product, of which the industrialisation was carried out during the last year. Currently, the latest modifi cations are being implemented based on the returns from the validation stage and it is expected that in the month of April 2008 the marketing can commence. In parallel to the development of this standard product, the sales have already started of personalised products based on the same technology.

Product or serviceSystem of multiple mini-bioreactors for performing screening experiments on animal cells. This consists of two parts:> Plastic bases of 6 mini-bioreactors, for single usage. Each reactor includes inoculation septum, fi lters for the entry of gases, an agitation system and probe ports.> Work station. Machinery where the mini-bioreactor bases are located.

Market As the product has applications in sectors such as the environmental industry, cosmetics, chemical synthesis, we are aiming ourselves mainly at biotechnology companies, specifi cally those carrying out production based on animal cells. The market where we are aimed at present is Europe, and in the coming years strategies will have to be established for entering the US/Canada market.

Team and shareholdersBusiness team: Andreu Fontova, Albert Soley, Xavier López, Francesc Gòdia, Ramon Bragós and Jordi Joan Cairó. This team holds the majority participation in the company at present.

Financing proposal The company has fi nancial needs of 200,000€, which will basically serve for extending the structure, contracting personnel in order to be able to meet production and marketing needs, and manufacturing a limited number of products, which in part will form stock, and in part will be products which will be used for rentals and assignments to leading companies and research groups.

Proposal summaryRound: Yes / New round: Yes / Type of investors: International

HEXASCREEN CULTURE TECHNOLOGIES

CIF: B-63893457VE3B, Edifi ci M, Campus UAB

08193 Bellaterra. [email protected]

Tel. 935 813 700

CONTACT PERSON ALBERT SOLEY ASTALS

#17Development, manufacture and marketing of equipment for screening in biotechnology.



As an entrepreneur, with which of the following qualities do you most identify, and why? The ability to take risks, the ability to innovate, the ability to motivate or the ability to organise.In my view, innovating and taking risks should be two essential qualities of any technology based enterprise. As far as the other qualities are concerned, I have a preference for the ability to be organised and persevere to achieve set goals.Albert Soley i Astals. Founding partner

048

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

EG

row

th


� 2006 2007 2008 2009 2010

TURNOVER 14.400 26.000 144.000 592.000 1.032.000

EBITDA -423 11.328 -90.000 218.000 517.000

RESOURCES 28.673 31.794 156.000 300.000 600.000

NEEDS - - 200.000 0 0

3

1

2


1

Tax code (CIF): B-63641229Granollers, 308170 Montornès del Vallès, Barcelonainfo@infi nitec.eswww.infi nitec.esTel. 934 020 162

CONTACT PERSON: ALFONS HIDALGO

As an entrepreneur, with which of the following qualities do you most identify, and why?

The ability to take risks, the ability to innovate, the ability to motivate or the ability to organise.

The ability to take risks. I think this is by far the quality I identify with the most. When

I look back on the past three years, I realise how much is at stake. It is undoubtedly one

of the biggest challenges of my life.Alfons Hidalgo, founding partner



3

#18INFINITEC ACTIVOS, SL

To provide the cosmetics market with the technology and innovation that both the research groups with which we work

and our own R&D department can deliver in order to encourage the transfer of technology in the form of highly effi cient new assets.

Company overviewThe company was set up in October 2004. It has a portfolio of approximately 20 products with a global network of 44 distributors, of which 20 are active buyers. We have 2 investor partners: BCN emprèn and Innova31. We have 2 sites: one manufacturing site in Montornès, and R&D and administrative offi ces in the Hèlix building of PCB, within the bioincubator.

Product or service Active ingredients for the cosmetics industry, biopeptides and nanotechnology-based release systems. Peptides are used because of the high effi ciency of these molecules and the possibility of reproducing/modulating activities which occur naturally in skin cells.The use of release systems is aimed at directing the encapsulated ingredient towards the target cell, and thus reduce the concentration of active ingredients while at the same time increasing activity.

MarketOur direct market is that of manufacturers of skin treatment cosmetics. On a worldwide scale, this market represents 240 billion Euros. The global market for active ingredients generates 450 million Euros and is set to reach 1 billion Euros by 2012. It is a constantly growing market, and emerging markets such as China are expected to experience the strongest growth.The type of product and technology we sell allows us to target both the premium luxury market and the mass market.

Team and shareholdersThe team is made up of six people: the two founders who are responsible for management and sales; production: two people; administration: one person; R&D: one person; and three more R&D contractors from external research groups. Two investor partners: BCN emprèn and Innova 31, and two minority shareholders providing fi nancial and scientifi c advisory services. We also employ three external advisors.

Financing proposalWe are looking for the capital to fi nance the new incorporations, the research equipment, as well as having fi nance for our sales operations, with visits to clients in 44 countries. We are preparing the company for a qualitative leap forward, our aim being to reach sales of 5.5 million Euros by 2010.

Proposal summary Round: Yes / New round: Yes / Type of investor: national and international

2

049

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

EG

row

th


� 2006 2007 2008 2009 2010

TURNOVER 623.322 849.242 1.748.789 3.822.762 5.568.712

EBITDA -140.000 -25.531 210.245 573.000 946.560

RESOURCES 60.911 135.380 345.625 918.625 1.865.185

NEEDS - - 500.000 500.000 500.000


Company overview Infociencia was founded in 1998 as a Contract Research Organization (CRO) to work in health science research. Since then, it has developed projects in all areas of clinical research, from clinical trials for recording to epidemiological studies using innovating technology. Currently it employs over one hundred people. The positive growth and development of the company since its creation is due to the efforts, interest and enthusiasm in discovering new technological solutions and new advanced concepts in service which are advantageous for clients.

Product or servicePioneering company in the implementing of electronic tools for carrying out clinical studies. Among the services offered by the company is that of the developing of projects in the areas of clinical research and knowledge extraction, using latest generation mobile applications and IP and GRID technology advanced applications. The areas of specialization are: Area of telemedicine. Area of clinical research and Area of biotechnology. Furthermore, co-ordinates and develops research projects jointly with other national and international research centres.

MarketThe market at which the products and services offered by Infociencia are aimed is mainly the pharmaceutical industry. Among the clients of Infociencia are 18 of the 120 leading pharmaceutical laboratories present on the Spanish market, while supplying in Europe has enabled the entering into contact with other companies within the sector.

Team and shareholdersThe management team consists of doctors of science, specialised in biocomputing, biotechnology, medicine and pharmacy: Jordi Naval (Chairman), Dr José Manuel Mas (Technical Director and head of R&D), Ramon Banet (Director of Strategic Marketing), Xavier Molina (Medical Director) and Esther Ramírez (Business Development).

Financing proposalInfociencia invests constantly in the development of new technological. This implies an important need for R&D fi nancing, without which the business profi tability achieved in recent years would be impossible.

Proposal summaryRound: no / New round: yes / Type of investors: national and international

INFOCIENCIA, SL CIF: B-61832036Balmes, 86, pral.08008 Barcelona

[email protected]

Tel. 932 158 008

CONTACT PERSON: JORDI NAVAL CHAMOSA

#19Clinical Inspiration: integrated clinical research management.



What has been your biggest business mistake and what did you learn from the experience?At the outset, urgent matters left no room for important ones. Consequently, we came to have a company lacking in the appropriate structure. Obviously, our own needs and natural selection have made us improve. What I learnt was: to think fi rst, then work... and obviously now this is what we do. Jordi Naval Chamosa, Chairman of Infociencia

3

050

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

EG

row

th /

pre

mis

es /

R&

D

1

2


� 2006 2007 2008 2009 2010

TURNOVER 13.071.546 9.167.718 10.267.845 11.808.021 13.815.385

EBITDA 488.786 129.153 144.651 166.349 194.629

RESOURCES 1.225.358 1.417.535 15.52.513 1.707.738 1.878.512

NEEDS - - 835.000 920.000 1.000.000


1

CIF: B-63192793Vilana,12. Despatx 15908022 [email protected]. 933 933 159

CONTACT PERSON: ROBERT SOLER RICH

If an overnight miracle took place and you woke up to the company of your dreams, what would be

the first change that you would notice on arriving at the office in the morning?

I would probably not have the incentive or problems I have at present regarding the developing of

projects which are world leaders and which can benefi t a large part of the population (patients with various serious pathologies), but I would have the satisfaction of seeing these objectives met and seeing the results we have dreamed of become reality, both through the results of the patients as well as through the results of the creation of a new line of business in medicine called advanced

therapies or regenerative therapy - a new specialisation and a new form of business?

Robert Soler Rich, Medical Director and manager



3

#20INSTITUT DE TERAPIA

REGENERATIVA TISSULAR S.L.Company devoted to regenerative medicine with twO lines of work:

infi ltrations of PRP and the regeneration of tissues from bone marrow stem cells and future projects of tissue regeneration.

Company overviewCompany created in 2003 with a great growth impulse, devoted to applied and translational therapies in the fi eld of regenerative medicine with autologous products:PRP (platelet concentrate). Consolidated therapy in forms of infi ltrations with natural anti-infl ammatories. Bone marrow stem cells for: Bone regeneration in fractures, Bone regeneration in femoral head osteonecrosis and Regeneration of cartilage and intervertebral disc.

Product or serviceOur company works with autologous products (of the patients themselves) carrying out the extraction, preparation (cultivation and expansion) and application of the same. All these products go through an animal clinic trial stage then a human clinic trial stage ending up with a consolidated product for treatment on humans fulfi lling all legal requisites, PEI granted by the AEMPS. Our company also acts as the manager of regenerative therapy with various groups of the state of the performing advisory duties and as an applying group.

MarketAt present, regenerative medicine is undergoing strong growth. Our company is already consolidated in PRP infi ltrations and natural anti-infl ammatories for different pathologies of the locomotor apparatus such as stem cell treatment of fractures and femoral head osteonecrosis. We believe such treatment has a potentially broad market but that the true market opportunity is in the new lines of regeneration both of cartilage for patients with arthrosis of the joints.

Team and shareholders The team is made up of two founding partners (doctors), two secretaries, two qualifi ed nurses and sub-contracting from the CTTC (formerly BST) in Vall d’Hebron for cellular production, as well as the sub-contracting of different companies for the development of the animal experimental stage at the UAB-Hospital Clinic Veterinari.

Financing proposalThe projects to be developed are multiplied, as is the need for the fi nancing for carrying them out. Always thinking that the fi nal objective is the creation of regenerative therapy units and for our company it is diffi cult to establish a sales fi gure for the subsidy to be requested, we believe this should be done according to the different stages.

Proposal summaryRound: No / New round: Yes / Type of investors: national and international

2

051

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

EG

row

th /

R&

D


� 2006 2007 2008 2009 2010

TURNOVER 157.500 232.077 1.500.000 3.000.000 15.000.000

EBITDA -10.768.54 25.334.94 - - -

RESOURCES 0 0 50% 50% 50%

NECESSITATS - - 50% 50% 50%


Company overviewThe company was created in June 2007. Currently, scientifi c-computational services are being invoiced to various clients within the biomedical fi eld and we have been granted various public subsidies for R&D. The company is located in the Bioincubator of the Parc Científi c de Barcelona - Banco de Santander. Intelligent Pharma has already attended an international trade fair in the sector and has had its participation confi rmed in the BioEurope 2008 trade fair (Madrid, April 2008) and Bio2008 (San Diego, USA, June 2008).

Product o serviceIntelligent Pharma provides scientifi c-computational services to companies within the biomedical fi eld. Specifi cally, 2 lines of service are offered: the consultancy and execution of made-to-measure research projects in computational chemistry and, the development of made-to-measure software systems The software systems developed may be in reference either to the scientifi c fi eld of biopharmaceutical development, or the technical fi eld.

Market The market consists of all those European companies developing their own biomedical research processes. This description includes research companies within the pharmaceutical, biotechnological, cosmetics, bio-food products or agrochemical sectors.

Team and shareholdersThe business team consists of Ignasi Belda, Laia Navarro and Prof. Ernest Giralt. Ignasi Belda is a computer engineer and expert in artifi cial intelligence applied to the solving of biomedical problems. Laia Navarro is an expert in R&D+i in new technologies. Professor Ernest Giralt, professor of organic chemistry at the Universitat de Barcelona, is a researcher of renowned international prestige. The fi nancial needs of the company have been partially covered to date by the capital risk company InverAlcoy.

Financing proposalIntelligent Pharma has undertaken various research projects in new computational technologies applied to biomedical research. We have been granted a large number of public subsidies which clearly do not cover all the investment. The investment required currently is to be devoted to fi nancing and complementing the subsidies granted.

Proposal summaryRound: yes / New round: yes / Type of investors: national and international

INTELLIGENT PHARMA CIF: B-64574221Parc Científi c de Barcelona,

Baldiri Reixac, 1008028 Barcelona

[email protected]

Tel. 934 034 551

CONTACT PERSON: IGNASI BELDA

#21Providing our clients, within the scope of biomedical research, with scientifi c -computational services which help to accelerate their research processes, to reduce development costs and reduce risks.



As a businessman, with which of the following qualities do you most identify, and why? The ability to take on risks, the ability to innovate, the ability to motivate or the ability to organise.The capacity to assume risks is essential for an entrepreneur. However, I think that a good businessman does not stand out especially in any of the foregoing options, but rather the overall sum is above that of a non-businessman. I see myself as within this profi le, but it is possible, bearing in mind my basic training in computer engineering, that I have signifi cant capacity for organisation, and thanks to my doctorate studies, I also have a noteworthy capacity for innovation.Ignasi Belda, CEO

3

052

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

EG

row

th /

R&

D

1

2


� 2006 2007 2008 2009 2010

TURNOVER - - 250.000 700.000 1.200.000

EBITDA - - 35.000 160.000 320.000

RESOURCES - - 246.000 210.000 350.000

NEEDS - - 150.000 0 0

qÜêÉÉ=íÜáåÖë=ÇÉÑáåÉ=~=íê~àÉÅíçêó

The start, the destination and thefootprint that you leave along the way

Each step is both a goal and a start in itself, as well as a chance to grow in the face of new projects and movecloser to the target.

At Deloitte we are aware that the progress made by each one of our professionals and clients impliesthat we grow as a Firm. For this reason we employ the latest technologies so that we can share all theexperience and knowledge of our global network madeup of approximately 150,000 professionals in over 140 countries, with more than 4,000 professionals located in Spain.

The specialisation, experience and multidisciplinaryapproach of each and every one of our professionals is therefore made available to our clients. Our leadingposition and presence in the most cutting edge projectsand industries in the economy are the result of years of experience in helping our clients to achieve their goals.

ïïïKÇÉäçáííÉKÉë

^ìÇáíKq~ñK`çåëìäíáåÖKcáå~åÅá~ä=^ÇîáëçêóK

Anuncio general jorn CIDEM Ing (march 08):Maquetación 1 26/02/2008 12:28 Página 1


Company overviewWe have just started production of the fi rst devices for research.

Product or service IoC-View, anaesthesia depth monitor, capable of evaluating the degree of consciousness of a sedated patient and of avoiding intra-operational awakening, which, should it occur due to poor anaesthesia practice, can cause serious disorders to the patient.

Market On a national level, the market is mature to admit products in any operating theatre. On a worldwide scale, we calculate a market potential of 25,000 units in Europe and more than double that in the USA.

Team and shareholders Erik Weber: 47%, Engineer responsible for patents, R&D and Production. Hector Litvan: 33%, Anaesthetist , head of cardiac Anaesthesiology at the Hospital de Sant Pau in Barcelona. Carlos Magaña: 20%, IESE and in charge of administration and sales.

Financing proposal We will assign 10% of the capital, and we currently value the company at 3 million euros. We have a solid project, capable of being transferred with value in a maximum period of 3 years.

Proposal summaryRound: No / New round: Yes / Type of investors: International

MORPHEUS MEDICAL CIF: B-64202971Llacuna, 162. Edif. Barcelona Activa


www.morpheus-medical.comTel. 933 090 668

CONTACT PERSON: CARLOS MAGAÑA

#22To offer innovating products to the sector of medical diagnosis, protected by our own patents.



What has been your biggest business mistake and what did you learn from the experience?Assuming that aid and subvention requested had already been obtained. They are obtained in the end, but usually late, and they should not be taken into account in the short term. This has caused some cash-fl ow problems. Carlos Magaña, General Manager

3

054

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

EG

row

th /

R&

D

1

2


� 2006 2007 2008 2009 2010

TURNOVER 3.000 55.000 300.000 600.000 2.000.000

EBITDA - - - - -

RESOURCES 90.000 90.000 90.000 90.000 120.000

NEEDS 100.000 300.000 300.000 350.000 0


1

CIF: B-20822334Ceramistes 208290 Cerdanyola del Vallès. [email protected]. 935 944 726

CONTACT PERSON: LLUÍS CHICO ROCA

If an overnight miracle took place and you woke up to the company of your dreams, what would be the fi rst change that you would notice on arriving

at the offi ce in the morning?That we have more time and resources for thinking and planning future strategies and new products, thus

enabling us to do things even better.Lluís Chico Roca, General Manager



3

#23NEOS SURGERY, SL

NEOS creates solutions to challenges in Neurosurgery. NEOS adds value to your implantable devices by merging new technologies and innovative

materials. Your implants are thus: easily used, without instruments, personalised, self-adjustable and radiotransparent.

Company overview NEOS was set up in 2003. In 2004 it gained a NEOTEC-CDTI loan. In 2006 it gained a patent for its fi rst product, BHID, and began to market it. The European ‘CUSTOM-IMD’ R&D project for the development of customisable prostheses with a global budget of 10M� began in 2007 and it gained a patent for a new line of cranial products called EAZIP. It won the Excellent Entrepreneurship Award in the ITF Forum in Barcelona.

Product or service NEOS has been marketing the BHID since July 2006, and develops short and mid-term products including the EAZIP family and spinal column applications respectively. Current products are covered by Spanish and European priority patents. BHID is a smart cranial immobilisation system made with materials with shape memory that is instruments-free and suitable for post-operative immobilisation of a craniotomy. The EAZIP family are implants for the cutting area of a craniotomy.

Market The specifi c European, North American and Japanese Cranial Fixations device markets (target market for NEOS) come to around 242$ million (approx. 170� M). The marked potential for spinal column applications is �725 million. NEOS faces its most signifi cants competition from microplate systems and clamp immobilisation systems. The world leader is Synthes (microplate systems). In Europe our biggest competitor is Aesculap, while in the American market we face Synthes, Lorenz Surgical and Stryker.

Team and shareholdersShareholders:management staff, Fundació Inasmet, Fons Sortek, Fundació Privada Ascamm, Mt Grup Gestió i Desenvolupament. The team: Lluís Chico Roca, CEO and cofunder. Igor Aristizabal, management assistant. Montse Charles-Harris, operations director.

Financing proposalThe fi nancing required for ndustrialisation, certifi cation, marketing and market launch comes to �1 million. Our plan is to sell initially via national and/or regional distributors in the European market. In a second stage (2009), we will use the visibility acquired in Europe as the launch pad for entry into American market.

Proposal summaryRound: Yes / New round: Yes / Type of investors: national and international

2

055

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

EG

row

th /

R&

D


� 2006 2007 2008 2009 2010

TURNOVER 63.000 0 100.000 1.200.000 3.300.000

EBITDA - -70.000 -40.000 200.000 1.600.000

RESOURCES - 150.000 200.000 900.000 2.000.000

NEEDS - - 500.000 500.000 -


Company overviewThe team joined the company on October 26th 2007. The lab is fully equipped and operational. Scientists are currently in the initial stages of technological research and development

Product or service The technology developed by Omnia Molecular will make it possible to rapidly identify new compounds with antibiotic potential, allowing the company to enter the anti-infectives market through two distinct channels: 1.- by carrying out in-house pharmacological development programmes; 2.- using the technology to provide screening services to other companies interested in discovering active compounds in proprietary libraries or against infectious diseases of their interest.

MarketThe global anti-infectives market is worth 41000M$ per year, most of which (33000M$) goes to antibiotics. The antibiotics market is estimated to grow at an annual rate of 6%. The antifungal compounds market is estimated to be worth 4500M$ per year, and although it has stabilised in the last few years, it is likely to grow in the future.

Team and shareholdersCurrent shareholders: Lluís Ribas de Pouplana, Eugeni Roura i Escapa, Joan Gargallo i Costa, Miriam Royo i Expósito, Joan Ribas de Pouplana and ‘Caixa Capital Semilla, S.C.R. de Régimen Simplifi cado, S.A.’ (Societat Unipersonal).Team: three biologists (Teresa Bori, Merche Fabra and Felix Atencio), one chemist (Josep Farrera) and a manager (Lourdes Saltó).

Financing proposalFirst development stage based exclusively on technology. In the last quarter of 2008, it plans to start its commercial activity proper, by drawing up a list of target companies and ranking of top clients. The fi rst commercial and technology visits are scheduled for the fi rst half of 2009. The fi rst ad hoc scientifi c projects are expected to be drawn up during the second half of 2009, with the fi rst commercial contract being expected to be signed by the end of the year. The fi nancing requirements are based on the assumption that the sales plan will be delayed by two years.

Proposal summaryRound: yes / New round: yes / Type of investors: national and international

OMNIA MOLECULAR, SL Tax code (CIF): B-63874069Josep Samitier, 1-5


www.omniamol.comTel. 934 020 158

CONTACT PERSON: LOURDES SALTÓ

#24OMNIA MOLECULAR, SL is a biotechnology company that develops a new method of antibiotic discovery. Its main activities are: the discovery of new enzyme inhibitors for use as antibiotics, and the development of new strategies for identifying active compounds.



As an entrepreneur, with which of the following qualities do you most identify, and why? The ability to take risks, the ability to innovate, the ability to motivate or the ability to organise.With the fi rst two qualities: taking risks and innovating. I identify with them most because they come quite naturally to me - and without too much effort.I fi nd that managing people is more diffi cult and requires more efforts.Lluis Ribas de Pouplana

3

056

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

EG

row

th /

R&

D

1

2


� 2006 2007 2008 2009 2010

TURNOVER 0 0 500.000 2.620.000 3.120.000

EBITDA -32.253,65 -24.139,62 -200.000 -300.000 -400.000

RESOURCES 56.818 256.818 256.818 256.818 256.818

NEEDS - - - 400.000 450.000


� 2006 2007 2008 2009 2010

SALES 51.000 101.000 1.215.000 3.037.000 10.075.000

GROSS PROFIT 35.000 63.000 858.000 2.135.000 6.900.000

EMPLOYEES - 1 - - -

1

Kwikaard 104Zoersel B-2980 BelgiumTel +32 [email protected]

CONTACT PERSON: PATRICK ROSA

Why should you be supported by cross-border investors?As medical issues are a worldwide problem, Cordatec

also sees itself as a global business. Cordatec’s competitive advantage lies in the ideal mix of having patented products, evolved from a genuine need in the medical fi eld and developed very closely with its users.

Patrick Rosa, CEO



#25CORDATEC NV

Cordatec is a company that develops, manufactures and commercialises innovative ideas

and technologies for cardiology, cardiac surgery, anaesthesiology and intensive care.

Company OverviewFor our fi rst product, the A-View catheter, we managed to obtain CE label and FDA approval.As we thrive on IP rights, we already have one product fully internationally patented and patents pending for 2 follow-up products.

Product or ServiceCordatec has one commercial product on the market, the A-view balloon catheter. The A-View catheter makes it possible to see the degree of atherosclerosis in the ascending aorta prior to sternotomy. This way, the surgeon has the possibility to change the operation strategy and thus drastically reduce the possibility for postoperative neurological complications, caused by emboli merging from 3% to 1%. For The Netherlands this accounts for an annual reduction of 450 to 150 patients or a structural cost saving of 6 million Euros per year.

MarketWithin the medical industry, Cordatec focuses on the niches of cardiology, cardiac surgery, anaesthesiology and intensive care products. Management believes that Cordatec’s products will facilitate the treatment of heart diseases which include arrhythmias and heart failure, as well as vascular diseases which include coronary and peripheral artery disease, and aortic aneurysm. Heart disease affl icts nearly 22 million people worldwide each year, of which about 5% receive therapy annually.

Team and ShareholdersCordatec NV is a development stage company which effectively started in 2003. We have already attracted international private investors.

Business PropositionAs an international-oriented company, Cordatec wishes to seek international capital. Funds will be used to invest in sales and marketing, especially in order to expand European sales, as well as to enter into the US market. The other aspect to invest in is product development (4 new emerging products). Funds required: Up to �2,000,000

Proposal SummaryRound: Yes / New round: - / Type of investors: international

2

057

Gro

wth

/ R

&D


3

INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

E

Company OverviewThe company started to function with full-time employees in 2002. The turnover has increased more than 10-fold during 2002-2007 and the last four years have been profi table. The increase in sales is mostly due to the development of new products through government-funded R&D projects. International sales have increased to 80% of total turnover in 2007.

Product or Service The products of Pharmatest are various cell culture models and animal models of osteoporosis, cancer-induced bone disease and osteoarthritis, which are offered to the pharmaceutical industry as contract research services. Using these models saves time and money for the pharmaceutical industry in the preclinical phase of drug discovery. The models are fast and reliable, and they are performed with high scientifi c expertise. All models are constantly updated according to the most recent scientifi c know-how.

Marketwe have calculated the amount of external R&D costs of the pharmaceutical industry for preclinical phases of osteoporosis drug development to be more than 100 million Euros. This fi gure is increasing rapidly due to increased development of new osteoporosis drugs and increased outsourcing trends in the pharmaceutical industry. Our primary market potential is in Western Europe, USA and Japan.

Team and ShareholdersThe management team has strong scientifi c expertise in bone and cancer biology, including much experience in preparing scientifi c publications and presentations, as well as 10 years experience in managing Pharmatest’s early growth.The existing investor, AVera, a public start-up foundation, is interested in investing more in Pharmatest in this coming round of fi nancing.

Business PropositionThe investment will be used for international marketing and R&D, enabling signifi cant value increase and success in 5 years. Funds required: Up to �1,000,000.

Proposal summaryRound: Yes / New round: - / Type of investors: international

PHARMATEST SERVICES LTD Itäinen Pitkäkatu 4CTurku 20520 Finland

Tel. +358 [email protected]

www.pharmatest.fi

CONTACT PERSON: JUSSI HALLEEN

#26Our mission is to speed up your drug discovery with our fast and reliable cutting-edge testing services.



What is your unique selling point?Pharmatest’s USP is the fast and reliable analyses performed with high scientifi c expertise. Pharmatest’s models have been developed through many years of careful optimisation and validation, and these analyses can not be repeatedly performed with the same quality outside Pharmatest. Jussi Halleen, CEO

3

058


� 2006 2007 2008 2009 2010

SALES 821.000 868.000 1.100.000 1.500.000 2.500.000

GROSS PROFIT 572.000 554.000 690.000 1.010.000 1.770.000

EMPLOYEES - 13 - -

Gro

wth

/ R

&D

1

2


INV

ES

TM

EN

T P

UR

PO

SE >

< S

TAG

E

Date post:	07-Jul-2020
Category:	Documents
Upload:	others
View:	5 times
Download:	0 times

BIOTECHNOLOGY AND LIFE SCIENCES -...

Documents